Pharmaceuticals

CSPC Innovation

CSPC Innovation released FY2026 Q1 earnings on April 27 Pre-Market (BJT), actual revenue CNY 664.65 M, actual EPS CNY -0.0674

CSPC Innovation to Release FY2026 Q1 Earnings on April 28 Pre-Market BJT

CSPC Innovation released FY2025 Annual Earnings on March 16 During-Market (BJT), Actual Revenue: CNY 2.158 B (Forecast: CNY 2.806 B), Actual EPS: CNY -0.1731 (Forecast: CNY 0.4547)

CSPC Innovation released FY2025 Q4 earnings on March 16 During-Market (BJT), actual revenue CNY 564.67 M, actual EPS CNY -0.1548

CSPC Innovation to Release FY2025 Earnings on March 17 During-Market (BJT), Forecast Revenue CNY 2.806 B, EPS CNY 0.4547

New 纶威's Subsidiary Receives NMPA Approval for Clinical Trials of SYS6023

Newnow and AstraZeneca Sign Strategic Collaboration Agreement for Innovative Peptide Molecule Development

NeoWis Holdings' Subsidiary Receives Clinical Trial Approval for SYS6090 Injection

CSPC Innovation released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 543.46 M, actual EPS CNY -0.0149

CSPC Innovation released FY2025 9 Months Earnings on October 27 After-Market BJT, Actual Revenue: CNY 1.593 B, Actual EPS: CNY -0.0161

CSPC Innovation to Release FY2025 Q3 Earnings on October 28 After-Market BJT

CSPC Innovation released FY2025 Q2 earnings on August 15 Pre-Market (BJT), actual revenue CNY 577.59 M, actual EPS CNY 0.0179

CSPC Innovation released FY2025 Semi-Annual earnings on August 15 Pre-Market (BJT), actual revenue CNY 1.05 B, actual EPS CNY -0.002

CSPC Innovation to Release FY2025 Semi-Annual Earnings on August 16, 2025 (BJT)

Xinnuo ESG Rated A by Huazheng Index

Xinnuo's Subsidiary Receives a 60 Million Yuan Government Subsidy

Jushi Biotech's SYS6040 Clinical Trial Application Approved by FDA

Xin Nuo Wei's stock price rises, Dongwu Securities gives buy rating

Food and Beverage ETF Turns Red in Afternoon, Policy Boosting Market Confidence

XinNuoWei Stock Price Rises, Earning Eastwu Securities Buy Rating

09995

688331

300765

159849

520880

512290

China's pharmaceutical industry is rapidly evolving, with major companies like CSPC Pharmaceutical and RemeGen securing significant out-licensing agreements. The shift from low-cost manufacturing to high-value innovation is evident, particularly with the integration of AI in drug discovery. AI is compressing preclinical timelines and enhancing R&D capabilities. China now accounts for 30% of the global experimental drug pipeline and is a leader in antibody-drug conjugate projects. This growth has raised concerns among US lawmakers about China's potential dominance in the global pharmaceutical supply chain.

SCMP

REMEGEN

RemeGen

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

China’s drug makers are speeding up – will AI be their secret weapon?

01237

The Beijing Stock Exchange released an announcement on the evening of April 9, announcing that Zhongkeyi will adopt the offline inquiry method for its issuance. This marks the Beijing Stock Exchange's restart of offline inquiry-based issuance after a three-year hiatus, the first such instance since the issuance of Inovance in March 2023

Wallstreetcn

CH ENV TECH&BIO

Beijing Stock Exchange Restarts Inquiry-Based Issuance After Three Years

516930

159992

520500

159316

159892

588130

159837

512010

SSY Group Wins NMPA Approvals for New Electrolyte and Antiemetic Injections

Tip Ranks

Minsheng Royal CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

SSY Group Wins NMPA Approvals for New Electrolyte and Antiemetic Injections

562050

CSPC Wins China Approval for New Aprepitant Injection to Strengthen Antiemetic Portfolio

Hwabao WP CSI Pharmaceuticals ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

CSPC Wins China Approval for New Aprepitant Injection to Strengthen Antiemetic Portfolio

560600

159859

01093

516820

UBS released a research report listing investment ratings and target prices for healthcare stocks. Hengrui Pharma is rated as Buy, with the target price raised from RMB 96.9 to RMB 98.3; Hansoh Pharma is rated as Buy, with the target price raised from RMB 48.2 to RMB 51.5; Sino Biopharmaceutical is rated as Buy, with a target price of RMB 12.2; 3SBIO is rated as Buy, with a target price of RMB 41; CSPC Pharma is rated as Neutral, with the target price raised from RMB 10 to RMB 10.9; Simcere Pharma is rated as Buy, with a target price of RMB 16.3; United Lab is rated as Buy, with a target price of RMB 18.9

AASTOCKS

Dacheng CSI All Share Health Care Equipment and Services ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI HK Equities Medical and Health Integration ETF

3SBIO

Huaan Hang Seng Biotech ETF

China Universal 800 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

HANSOH PHARMA

Founder Fubon CSI Medicine and Medical Device Innovation ETF

SIMCERE PHARMA

UNITED LAB

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

CSPC PHARMA

Hengrui Pharma

Ping An CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

SBP GROUP

UBS Investment Ratings and Target Prices for Healthcare Stocks (Table)

CSPC Pharmaceutical Group Ltd. announced a record $18.5 billion licensing deal with AstraZeneca, but its stock fell sharply by over 10% following the news. The deal, which includes rights to CSPC's anti-obesity drugs, was anticipated to boost CSPC's global market presence. However, investor disappointment stemmed from high expectations set by prior rumors, leading to a sell-off. Concerns about CSPC's corporate governance, following an insider trading case, may have further impacted investor confidence. The company is under pressure as its core drug business faces challenges from China's procurement policies.

benzinga_article

AstraZeneca PLC

AstraZeneca

Big Deal, Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca

CSPC Pharmaceutical Group has received drug registration approval in mainland China for its fast-acting intravenous antihypertensive drug, Clevidipine Injectable Emulsion. This drug is designed for patients whose hypertension is not effectively managed with oral therapy, offering rapid blood pressure control without the need for dose adjustments. The approval enhances CSPC's cardiovascular product pipeline and addresses the demand for acute-care hypertension treatments in Chinese hospitals. Analysts rate the stock as a Buy with a price target of HK$10.50.

CSPC Wins China Approval for Fast-Acting Intravenous Hypertension Drug

IBBQ

ARKG

Health-care stocks increased as traders shifted focus to the sector amid market instability. Eli Lilly announced a $3.5 billion plant for weight-loss drugs in Pennsylvania, while AstraZeneca partnered with CSPC Pharmaceuticals for obesity and diabetes drug rights. Pfizer and Merck saw gains ahead of upcoming earnings, but health insurers faced pressure from proposed Medicare reimbursement rates by the Trump administration.

- Health-care companies saw an increase as traders shifted towards the sector due to its perceived stability amidst unrest.  
- Eli Lilly announced plans for a $3.5 billion weight-loss drug plant in Pennsylvania, while AstraZeneca partnered with CSPC Pharmaceuticals on an obesity and diabetes drug portfolio valued in billions.  
- Concerns about the Trump administration's proposed Medicare reimbursement rates continued to pressure health insurers ahead of upcoming earnings reports from Pfizer and Merck.

MorningStar

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

Pfizer

iShares US Pharma

Ark Genomic Revolution ETF

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Eli Lilly

VG Health

Merck

Health Care Up After Defensive Rotation — Health Care Roundup

AstraZeneca (AZN) has entered the obesity drug market with an $18.5 billion collaboration and licensing deal with CSPC Pharmaceuticals. This agreement allows AZN to develop and sell CSPC's long-acting peptide medicines and utilize its LiquidGel platform for monthly injections outside Greater China and Taiwan. The deal includes a $1.2 billion upfront payment and potential additional payments of up to $17.3 billion based on milestones. AstraZeneca aims to diversify its portfolio and compete in a market projected to exceed $100 billion, with a current Strong Buy rating from Wall Street.

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

AstraZeneca (AZN) Moves Deeper into Weight Loss Market with New $18.5B CSPC Agreement

CSPC Innovation(300765.SZ)

China’s drug makers are speeding up – will AI be their secret weapon?

Beijing Stock Exchange Restarts Inquiry-Based Issuance After Three Years

SSY Group Wins NMPA Approvals for New Electrolyte and Antiemetic Injections

CSPC Wins China Approval for New Aprepitant Injection to Strengthen Antiemetic Portfolio

UBS Investment Ratings and Target Prices for Healthcare Stocks (Table)

Big Deal, Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca

CSPC Wins China Approval for Fast-Acting Intravenous Hypertension Drug

Health Care Up After Defensive Rotation — Health Care Roundup

AstraZeneca (AZN) Moves Deeper into Weight Loss Market with New $18.5B CSPC Agreement